Mechanistically, anlotinib suppresses the expression of TFRC by inhibiting the VEGFR2‐AKT‐HIF axis, which in turn enhances the secretion of CXCL14 and recruits tumour‐infiltrating CD8+ T cells, particularly PD‐1+CD8+ T cells, thereby potentiating the anti‐tumour efficacy of anti‐PD‐1 treatment. Here, CD8A is linked to neoplasm.